DiaCarta Inc. Receives CE Mark for Its Proprietary IVD Cancer Mutation Tests: KRAS, NRAS, EGFR and More
DiaCarta, a technology-driven translational genomics and molecular diagnostics company located in Hayward, CA developing the most precise diagnostic products for cancer and infectious disease, today announced it has received CE Mark for its proprietary in vitro diagnostics (IVD) cancer mutation tests QClamp™ KRAS including codon 146 and 117, NRAS including codon 146, EGFR including T790M, all deletions and insertions, BRAF, JAK2 and PIK3CA. These mutation test kits can derive results in 2 hours directly from samples including FFPE, blood, and tissues without DNA purification. In addition, these mutation kits are highly sensitive and can be used on any commercial available Real-Time PCR machines.
QClamp™ is a revolutionary new way to screen for somatic mutations, which utilizes a sequence specific wild-type template Xeno-nucleic acid “Molecular Clamp” (XNA) that suppresses PCR amplification of wild-type template DNA and allows selective PCR amplification of only mutant templates. This allows the detection of mutant DNA despite a large excess of wild-type template from any sample, including FFPE and whole blood.
The QClamp™ technology is particularly suited to “liquid biopsy” applications for the detection of tumor-derived, cell-free DNA in plasma or urine, which can achieve sensitivities equivalent or even better than droplet digital PCR (ddPCR). Utilizing only standard qPCR real-time instrumentation, QClamp™ Real-Time PCR mutation tests are highly sensitive and can detect mutated DNA even when the concentration is below 0.1%.
“The problem with sequencing technology right now, if you take a tumor sample, it’s like a big haystack with a few needles in it,” Dr. Mike Powell, DiaCarta’s chief science officer, a veteran of Boehringer Mannheim and Roche Diagnostics, comments. “What we do is we eliminate the haystack from the equation. We burn the haystack and amplify the needles,” he said. The method also improves mutation detection because “with our XNA clamp, if you get a single nucleotide polymorphism, the mismatch causes a 15 to 20 degree difference in [melt] temperature” — a 10-fold increase over other PCR methods, he said.
“Recent studies have demonstrated that DNA sequencing is one of the least sensitive methods for characterizing mutation with only 10-20% of mutated DNA detected.” DiaCarta CEO and Founder Dr. Aiguo Zhang added that “Consequently, tumor driver mutations may not be detectable using standard DNA sequencing methods, especially in liquid biopsy applications like whole blood. Our QClamp products are the best alternative tools for the unmet market need.”
About DiaCarta Inc.
DiaCarta, based in Hayward, Calif., is developing and commercializing precise molecular diagnostic cancer assays that enable the most sensitive, reliable, and accurate detection of cancer biomarkers directly from a patient sample, including QClamp gene mutation tests, SuperbDNA gene expression assays, and QZol, the only PCR ready lysate solution. DiaCarta’s NRAS, EGFR, KRAS, BRAF, and PIK3CA tests are highly sensitive and able to detect a broad set of mutations and are being used by hospitals and cancer clinical laboratories and by biotechnology and pharmaceutical companies for clinical research.
According to the recent FDA SARS-CoV-2 Reference Panel Comparative Data released on September 15, among all the FDA EUA tests with returned results, DiaCarta’s QuantiVirusTM SARS-CoV-2 Test and QuantiVirus™ SARS-CoV-2 Multiplex Test both rank within the top 3 for product sensitivity.
DiaCarta’s QuantiVirus™ SARS-CoV-2 Multiplex Test ranks among the top 10 kits in terms of low limit of detection (LoD). DiaCarta is the top 6 company, after Perkin Elmer, Roche, Quest, RTA and BD Biosciences.
DiaCarta Receives Regulatory COFEPRIS Approval in Mexico & ICMR Approval in India for its FDA EUA Approved QuantiVirus™ SARS-CoV-2 Test
DiaCarta Inc., a precision molecular diagnostics company with a unique, patented XNA technology platform for the development of novel liquid biopsy tests, announced today that its QuantiVirus™ SARS-CoV-2 test has been approved for distribution in Mexico.
DiaCarta SARS-CoV-2 Test Detecting 3 Viral Genes Receives US FDA Emergency Use Authorization & Test Manufacturing Expanded to 500K COVID-19 Tests/Week
DiaCarta Inc, a precision molecular diagnostic company in CA, announced Thursday the US FDA granted Emergency Use Authorization for DiaCarta’s proprietary QuantiVirus™ PCR diagnostic (Dx) test specifically detecting three different genes of SARS-CoV-2, the virus causing the COVID-19 pandemic. DiaCarta recently expanded manufacturing capacity to 500,000 tests per week and is planning to expand to even larger (4x) scale manufacturing to meet the increasing demand for PCR tests to monitor COVID-19.
DiaCarta Inc. has filed for EUA with the FDA and has received CE mark for its highly sensitive QuantiVirus™ SARS-CoV-2 Test Kit
DiaCarta Inc., a precision molecular diagnostic company, announced today that it has filed for Emergency Use Authorization (EUA) with the US FDA for its QuantiVirus™ SARS-CoV-2 test and has validated the COVID-19 diagnostic test in its own CLIA certified lab in Richmond, CA to provide testing services for healthcare providers and patients. DiaCarta recently received Conformitè Europëenne (CE) Mark for its product.